Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox® Antimicrobial Potency Study in Latin America (LA-ZAPS)
Linezolid was the first clinically applied member of the new antimicrobial class called the "oxazolidinones". These agents have a powerful spectrum of activity focussed against Gram-positive organisms including strains with documented resistances to other antimicrobial classes. We conducte...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
|
| Series: | Brazilian Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702002000300001&lng=en&tlng=en |
| _version_ | 1811341602811019264 |
|---|---|
| author | Charles H. Ballow Douglas J. Biedenbach Flavia Rossi Ronald N. Jones |
| author_facet | Charles H. Ballow Douglas J. Biedenbach Flavia Rossi Ronald N. Jones |
| author_sort | Charles H. Ballow |
| collection | DOAJ |
| description | Linezolid was the first clinically applied member of the new antimicrobial class called the "oxazolidinones". These agents have a powerful spectrum of activity focussed against Gram-positive organisms including strains with documented resistances to other antimicrobial classes. We conducted a multicenter surveillance (Zyvox Antimicrobial Potency Study; ZAPS) trial of qualifying Gram-positive isolates from 24 medical centers in eight countries in Latin America. The activity and spectrum of linezolid was compared to numerous agents including glycopeptides, quinupristin/dalfopristin, b-lactams and fluoroquinolones when testing 2,640 strains by the standardized disk diffusion method or Etest (AB BIODISK, Solna, Sweden). The linezolid spectrum was complete against staphylococci (median zone diameter, 29 - 32 mm), as was the spectrum of vancomycin and quinupristin/dalfopristin. Among the enterococci, no linezolid resistance was detected, and the susceptibility rate was 93.1 - 96.4%. Only the vancomycin-susceptible Enterococcus faecium strains remained susceptible (92.8%) to quinupristin/dalfopristin. Marked differences in the glycopeptide resistance patterns (van A versus van B) were noted for the 22 isolates of VRE, thus requiring local susceptibility testing to direct therapy. Streptococcus pneumoniae and other species were very susceptible (100.0%) to linezolid, MIC90 at 0.75 mug/ml. Penicillin non-susceptible rate was 27.7% and erythromycin resistance was at 17.4%. Other streptococci were also completely susceptible to linezolid (MIC90, 1 mug/ml). These results provide the initial benchmark of potency and spectrum for linezolid in Latin American medical centers. Future comparisons should recognize that the oxazolidinones possess essentially a complete spectrum coverage of the monitored staphylococci, enterococci and streptococcal isolates in 2000-2001. This positions linezolid as the widest spectrum empiric choice against multi-resistant Gram-positive cocci, a spectrum of activity greater than available glycopeptides and the streptogramin combination. |
| first_indexed | 2024-04-13T18:56:59Z |
| format | Article |
| id | doaj.art-12fdb4f6e8b644738abc36a7c78865f5 |
| institution | Directory Open Access Journal |
| issn | 1678-4391 |
| language | English |
| last_indexed | 2024-04-13T18:56:59Z |
| publisher | Elsevier |
| record_format | Article |
| series | Brazilian Journal of Infectious Diseases |
| spelling | doaj.art-12fdb4f6e8b644738abc36a7c78865f52022-12-22T02:34:12ZengElsevierBrazilian Journal of Infectious Diseases1678-43916310010910.1590/S1413-86702002000300001S1413-86702002000300001Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox® Antimicrobial Potency Study in Latin America (LA-ZAPS)Charles H. BallowDouglas J. BiedenbachFlavia RossiRonald N. JonesLinezolid was the first clinically applied member of the new antimicrobial class called the "oxazolidinones". These agents have a powerful spectrum of activity focussed against Gram-positive organisms including strains with documented resistances to other antimicrobial classes. We conducted a multicenter surveillance (Zyvox Antimicrobial Potency Study; ZAPS) trial of qualifying Gram-positive isolates from 24 medical centers in eight countries in Latin America. The activity and spectrum of linezolid was compared to numerous agents including glycopeptides, quinupristin/dalfopristin, b-lactams and fluoroquinolones when testing 2,640 strains by the standardized disk diffusion method or Etest (AB BIODISK, Solna, Sweden). The linezolid spectrum was complete against staphylococci (median zone diameter, 29 - 32 mm), as was the spectrum of vancomycin and quinupristin/dalfopristin. Among the enterococci, no linezolid resistance was detected, and the susceptibility rate was 93.1 - 96.4%. Only the vancomycin-susceptible Enterococcus faecium strains remained susceptible (92.8%) to quinupristin/dalfopristin. Marked differences in the glycopeptide resistance patterns (van A versus van B) were noted for the 22 isolates of VRE, thus requiring local susceptibility testing to direct therapy. Streptococcus pneumoniae and other species were very susceptible (100.0%) to linezolid, MIC90 at 0.75 mug/ml. Penicillin non-susceptible rate was 27.7% and erythromycin resistance was at 17.4%. Other streptococci were also completely susceptible to linezolid (MIC90, 1 mug/ml). These results provide the initial benchmark of potency and spectrum for linezolid in Latin American medical centers. Future comparisons should recognize that the oxazolidinones possess essentially a complete spectrum coverage of the monitored staphylococci, enterococci and streptococcal isolates in 2000-2001. This positions linezolid as the widest spectrum empiric choice against multi-resistant Gram-positive cocci, a spectrum of activity greater than available glycopeptides and the streptogramin combination.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702002000300001&lng=en&tlng=enLinezolidoxazolidinonesantimicrobial surveillanceresistant Gram-positive cocciZAPS |
| spellingShingle | Charles H. Ballow Douglas J. Biedenbach Flavia Rossi Ronald N. Jones Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox® Antimicrobial Potency Study in Latin America (LA-ZAPS) Brazilian Journal of Infectious Diseases Linezolid oxazolidinones antimicrobial surveillance resistant Gram-positive cocci ZAPS |
| title | Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox® Antimicrobial Potency Study in Latin America (LA-ZAPS) |
| title_full | Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox® Antimicrobial Potency Study in Latin America (LA-ZAPS) |
| title_fullStr | Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox® Antimicrobial Potency Study in Latin America (LA-ZAPS) |
| title_full_unstemmed | Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox® Antimicrobial Potency Study in Latin America (LA-ZAPS) |
| title_short | Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox® Antimicrobial Potency Study in Latin America (LA-ZAPS) |
| title_sort | multicenter assessment of the linezolid spectrum and activity using the disk diffusion and etest methods report of the zyvox r antimicrobial potency study in latin america la zaps |
| topic | Linezolid oxazolidinones antimicrobial surveillance resistant Gram-positive cocci ZAPS |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702002000300001&lng=en&tlng=en |
| work_keys_str_mv | AT charleshballow multicenterassessmentofthelinezolidspectrumandactivityusingthediskdiffusionandetestmethodsreportofthezyvoxantimicrobialpotencystudyinlatinamericalazaps AT douglasjbiedenbach multicenterassessmentofthelinezolidspectrumandactivityusingthediskdiffusionandetestmethodsreportofthezyvoxantimicrobialpotencystudyinlatinamericalazaps AT flaviarossi multicenterassessmentofthelinezolidspectrumandactivityusingthediskdiffusionandetestmethodsreportofthezyvoxantimicrobialpotencystudyinlatinamericalazaps AT ronaldnjones multicenterassessmentofthelinezolidspectrumandactivityusingthediskdiffusionandetestmethodsreportofthezyvoxantimicrobialpotencystudyinlatinamericalazaps |